All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-04-07.
From the record
ANI Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2020-05-14); an auditor change (8-K item 4.01, the latest 2026-04-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+23.9% a year over 10 filed years; profitable in 5 of 10.
From the record
ANI Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $129 million in fiscal 2016 to $883 million in fiscal 2025, up 23.9% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 5 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 9.3% a year. 9% of cash flow returned. Insiders: 50 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, ANI Pharmaceuticals, Inc.'s diluted share count grew about 9.3% a year, and dividends and buybacks returned about 9% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 50 sales (35 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 14%: 14¢ of profit per shareholder dollar. Leverage 62%: owes 62¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, ANI Pharmaceuticals, Inc. earned about 14 cents of profit for every dollar of shareholders' money. Leverage: it owed about 62 cents per dollar of assets, and net share issuance: its share count grew 9.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 19% of 315 in its family; net margin 8.7%.
From the record
ANI Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $883 million in fiscal 2025 ranks in the top 13% by size; a net margin of 8.7% ranks in the top 17%; revenue growth of 40.8% a year over the last 3 filed years ranks in the top 26% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 42% of 315 in its family for leadership; chief executive since 2020.
From the record
ANI Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lalwani, Nikhil (PRESIDENT & CEO, as filed), filing under that title since 2020-09-10, 6.2 years (top 37% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (bottom 42%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 35% of 273 in its family for room to expand.
From the record
ANI Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $286 million against debt of $292 million leaves -0.4% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is 19.4% of revenue (top 13%); research spending of 5.8% of revenue (bottom 5%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 21% of 306 in its family for growth drivers.
From the record
ANI Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 40.8% a year over the last three filed years against 23.9% over all 10, speeding up (top 15% of its family); the newest year grew 43.8% (top 28%); research spending grew 32.3% a year (top 13%); capital spending grew 15.9% a year (top 26%) (its annual reports). ANI Pharmaceuticals, Inc. reported 5 product lines in fiscal 2025: Sales of Generic Pharmaceutical Products at $384 million (44%), Sales of Cortrophin Gel at $348 million (39%), Sales of ILUVIEN and YUTIQ at $75 million (9%), and 2 more; 3 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 29% of 233 in its family for expectations against reality.
From the record
ANI Pharmaceuticals, Inc.'s newest year against its own record: revenue of $883 million in fiscal 2025 came in 3.2% above the $856 million its prior three years' pace pointed to (top 39% of its family); net income of $77 million against a prior three-year average of $18 million (top 2%); a net margin of 8.7% against -5.1% before (top 47%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made